Intra-Cellular Therapies, Inc
3 drugs in NADAC|0 Generic,3 Brand
Intra-Cellular Therapies, Inc lists 3 NDCs in the CMS NADAC file (0 generic, 3 brand), at an average NADAC of $57.23 per unit, with a week-over-week move of -0.0% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
3
0G / 3B
Avg Price / Unit
$57.2302
$57.20 – $57.25
Avg 7d Change
-0.02%
Across 3 drugs with changes
7d Activity
of 3 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
lumateperone market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Atypical Antipsychotic therapeutic class
Review the broader class where Intra-Cellular Therapies, Inc has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Intra-Cellular Therapies, Inc make?
Intra-Cellular Therapies, Inc lists 3 NDCs in the CMS NADAC file — 0 generic and 3 brand products.
What is the average price of Intra-Cellular Therapies, Inc drugs?
The average NADAC across Intra-Cellular Therapies, Inc's portfolio is $57.2302 per unit, ranging from $57.2004 to $57.2471.
What types of drugs does Intra-Cellular Therapies, Inc make?
Intra-Cellular Therapies, Inc makes drugs across 1 FDA pharmacologic class. The most common by NDC count are Atypical Antipsychotic (3).
Has Intra-Cellular Therapies, Inc had any drug recalls?
No FDA enforcement recalls are matched to Intra-Cellular Therapies, Inc in the openFDA feed.
How has Intra-Cellular Therapies, Inc's pricing changed recently?
Over the past 7 days, 1 Intra-Cellular Therapies, Inc product rose and 2 fell, with a portfolio-wide average change of -0.0%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
CAPLYTA 42 MG CAPSULE lumateperone | $57.2471 per EA | +0.02% |
CAPLYTA 10.5 MG CAPSULE lumateperone | $57.2430 per EA | -0.04% |
CAPLYTA 21 MG CAPSULE lumateperone | $57.2004 per EA | -0.05% |